Literature DB >> 8924260

Calcium antagonists: still appropriate as first line antihypertensive agents.

M Epstein1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8924260     DOI: 10.1016/0895-7061(96)00013-1

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


× No keyword cloud information.
  11 in total

1.  Differential effects of urapidil and doxazosin on heart rate.

Authors:  Kurt Stoschitzky; Gergana Stoschitzky; Manfred Wonisch; Helmut Brussee
Journal:  Eur J Clin Pharmacol       Date:  2007-01-16       Impact factor: 2.953

2.  Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study.

Authors:  Claudia Bucci; Muhammad M Mamdani; David N Juurlink; Jack V Tu
Journal:  Can J Cardiol       Date:  2008-08       Impact factor: 5.223

3.  Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease.

Authors:  Soosung Kang; Garry Cooper; Sara Fernandez Dunne; Chi-Hao Luan; D James Surmeier; Richard B Silverman
Journal:  J Med Chem       Date:  2013-05-23       Impact factor: 7.446

Review 4.  The use of calcium antagonists in the treatment of hypertensive persons with kidney disease.

Authors:  Sheldon Tobe; Murray Epstein
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 5.  Manidipine: a review of its use in hypertension.

Authors:  S M Cheer; K McClellan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Role of a third generation calcium antagonist in the management of hypertension.

Authors:  M Epstein
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 7.  Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.

Authors:  H D Langtry; C M Spencer
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

8.  CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease.

Authors:  Soosung Kang; Garry Cooper; Sara F Dunne; Brendon Dusel; Chi-Hao Luan; D James Surmeier; Richard B Silverman
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

Review 9.  Safety and tolerability of moxonidine in the treatment of hypertension.

Authors:  M Schachter; J Luszick; B Jäger; C Verboom; E Söhlke
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

Review 10.  Hypertensive Emergency in Aortic Dissection and Thoracic Aortic Aneurysm-A Review of Management.

Authors:  Prateek K Gupta; Himani Gupta; Ali Khoynezhad
Journal:  Pharmaceuticals (Basel)       Date:  2009-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.